COVID-19

COVID-19 treatments: under evaluation

The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.

COVID-19 treatments under marketing authorisation evaluation

EMA’s CHMP is evaluating marketing authorisation applications (which may be for conditional marketing authorisation) for the following COVID-19 treatments:

TreatmentApplicantStart of marketing authorisation evaluationMore information
Lagevrio (molnupiravir)*Merck Sharp & Dohme and Ridgeback Biotherapeutics 23/11/2021

Latest news

*This medicine can already be used in the EU to treat COVID-19, after EMA's CHMP completed a review under Article 5(3) of Regulation (EC) No 726/2004. For more information, see:

Withdrawn from marketing authorisation evaluation

Treatment developers have withdrawn the following COVID-19 treatments from the marketing authorisation evaluation process:

TreatmentTreatment developerKey milestonesMore information
Olumiant (baricitinib)Eli Lilly Nederland B.V.Marketing authorisation evaluation started: 23/11/2021

Withdrawn from marketing authorisation evaluation: 07/12/2022

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022

 

Withdrawn from rolling review

Treatment developers have withdrawn the following COVID-19 treatments from the rolling review process:

TreatmentTreatment developerKey milestonesMore information
Bamlanivimab and etesevimabEli LillyRolling review started: 11/03/2021

Withdrawn from rolling review: 29/10/2021
Latest news

Paediatric investigation plan for bamlanivimab

Paediatric investigation plan for etesevimab

Topics

How useful was this page?

Add your rating
Average
11 ratings
1 rating
2 ratings
11 ratings